Methods for treating psoriatic arthritis

Patent metadata

Field	Value
Publication number	US-10226443-B2
Application number	US-201514885084-A
Country	US
Kind code	B2
Filing date	Oct 16, 2015
Priority date	Oct 16, 2014
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.

First claim

What is claimed is:

1. A method for treating a subject afflicted with psoriatic arthritis, wherein the subject afflicted with psoriatic arthritis exhibits symptoms characteristic of psoriasis of the skin selected from the group consisting of pain, swelling, or stiffness in one or more joints; joints that are red or warm to the touch; dactylitis; pain in and around the feet and ankles; and lower back pain, and the subject does not exhibit symptoms characteristic of inflammatory bowel disease selected from the group consisting of abdominal pain; vomiting; diarrhea; rectal bleeding; severe pelvic cramps; and weight loss, the method comprising administering to the subject a therapeutically effective amount of at least one medium-chain fatty acid or an ester/salt thereof or a composition thereof selected from hexanoic acid and heptanoic acid or an ester/salt thereof, wherein the at least one medium-chain fatty acid or an ester/salt thereof or composition thereof is administered orally or anally, wherein the subject afflicted with psoriatic arthritis has decreased bacterial diversity of gut microbiota, and wherein administering the therapeutically effective amount of the at least one medium-chain fatty acid or an ester/salt thereof or composition thereof treats the subject afflicted with psoriatic arthritis.

2. The method of claim 1 , wherein the at least one medium-chain fatty acid is hexanoic acid or heptanoic acid.

3. The method of claim 1 , wherein the at least one medium-chain fatty acid or an ester/salt thereof or composition thereof is administered anally into at least one of the terminal ileum and right colon.

4. The method of claim 1 , wherein the decreased bacterial diversity of gut microbiota is determined by isolating a fecal sample from the subject and processing the fecal sample to generate a fecal bacterial sample; and analyzing microbiota diversity in the fecal bacterial sample using nucleic acid sequencing.

5. The method of claim 4 , wherein the nucleic acid sequencing is shotgun sequencing.

6. The method of claim 1 , wherein the subject meets three or more points from the ClASsification of Psoriatic ARthritis (CASPAR) criteria, including: (1) the presence of psoriasis (current, history of, or family history of), (2) psoriatic nail dystrophy, (3) a negative rheumatoid factor (RF) test result, (4) dactylitis (history of or current), and (5) radiographic evidence of juxta-articular new bone formation.

Assignees

• Scher Jose U
• Ubeda Carles
• Littman Dan R
• Pamer Eric G
• Abramson Steven B
• Koralov Sergei B
• Univ New York
• Memorial Sloan Kettering Cancer Center
• Fundacion Para El Fomento De La Investig Sanitaria Y Biomedica De La Comunitat Valenciana Fisabio

Inventors

• Scher Jose U
• Ubeda Carles
• Littman Dan R
• Pamer Eric G
• Abramson Steven B
• Koralov Sergei B

Classifications

• A61K35/74

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61K31/20 Primary

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title